Trial Profile
A study to evaluate the quantification and pharmacologic selectivity of a 5HT6 PET ligand 11C-GSK215083 and to measure occupancies achieved at various doses of SB742457 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 215083 (Primary) ; Intepirdine
- Indications Alzheimer's disease
- Focus Diagnostic use
- 28 Apr 2016 New trial record